Preliminary cardiac imaging at high-performance 0.55T MRI
Siemens Siemens Seed GrantNov 15, 2022 - Nov 14, 2023
Role: Co-Investigator
Description: This grant program is intended to support the initial stage of new research directions on the Siemens scanners at China Basin in preparation for attracting additional multiyear funding from extramural sources. |
Preliminary cardiac imaging at high-performance 0.55T MRI
Siemens Siemens Seed GrantNov 15, 2022 - Nov 14, 2023
Role: Primary Investigator
Description: This grant program is intended to support the initial stage of new research directions on the Siemens scanners at China Basin in preparation for attracting additional multiyear funding from extramural sources. |
Efficient and Comprehensive Advanced Magnetic Resonance Imaging of Hereditary Hemorrhagic Telangiectasia Vascular Malformations (AVIATOR)
NIH/CSR W81XWH2210178 (A139676)Aug 1, 2022 - Jul 1, 2026
Role: Co-Investigator
Description: Major Goals: The major goals of this project are to propose a paradigm shift in the evaluation of vascular malformations, a specific area of encouragement for the Investigator-Initiated Research Award. Patients with hereditary hemorrhagic telangiectasia (HHT), a genetic condition causing a high frequency of arteriovenous malformations (AVMs) in the brain, lung, and liver, will benefit from the development of an efficient MRI screening protocol for those organs to replace multiple types of MRI, CT, and ultrasound examinations currently used for screening. Additional development of targeted MR imaging techniques at 3T and 7T will better define the anatomic and physiologic features of multiorgan AVMs that stratify lesion risk, guide treatment decisions, monitor responses to therapy, and will save costs as compared to current methods that employ invasive catheter angiography. |
Imaging of Active Myocardial Fibrosis Using 68Ga-FAP-2286
Radiological Society of North America (RSNA) RSNA Research Scholar grantJul 1, 2022 - Jun 30, 2024
Role: Primary Investigator
Description: The overall goal of this project is to evaluate the ability of a novel imaging agent (68Ga-fibroblast activation protein (FAP)-2286) to detect active pathologic myocardial fibrosis. |
Improved Cardiac MRI: Fast, Free-Breathing, Quantitative, Without Contrast Administration.
Huntington Memorial Fund REAC AWARDJan 1, 2022 - Dec 31, 2022
Role: Co-Investigator
Description: Fast, Free-Breathing, Quantitative, Without Contrast Administration through parametric methods. |
SPIROMICS II: Heart Failure
NIH R01 HL093081Sep 20, 2019 - Jun 30, 2024
Role: Co-Investigator
Description: The overall objective of the SPIROMICS HF study is to examine heart-lung interactions to suggest new diagnostic and therapeutic strategies for COPD and HF. The study will examine specific cardiopulmonary pathophysiological abnormalities in a variety of COPD subtypes, with echocardiography as a key component in determining the cardiac pathophysiology that is unique to each COPD subtype. The other major components include a cardiopulmonary MRI and cardiac risk factors. |
Novel Arrhythmic Risk Screening Using Cardiac MRI and ECG Machine Learning in Mitral Valve Prolapse
UCSF, Cardiology Cardiology Innovation Award 7027291Jul 1, 2019 - Jun 30, 2022
Role: Co-Investigator
Description: These internal funds are supporting the creation of an MVP registry of consecutive MVP patients with ECGs, contrast-enhanced CMR and Holter monitors with the goal of developing ECG-based machine learning tools to detect arrhythmic MVP and its myocardial substrates. |
Evaluation of HIV- associated Cardiac Dysfunction in Women
NIH R01HL132794Jul 1, 2019 - Mar 31, 2021
Role: Co-Investigator
Description: Evaluation of HIV- associated Cardiac Dysfunction in Women Using repeated measures of HIV-specific exposures and ART, and added biomarkers of cardiac stress, inflammation and lipid dysregulation, this proposal stands to provide important new knowledge concerning the role of HIV infection and related factors in subclinical myocardial dysfunction and disease. In so doing, the proposed project will identify strategies and future research to avert the potential rise in symptomatic HF that threatens the HIV-infected population in the cART era. |
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)
NIH R33HL141047Feb 1, 2019 - Jan 31, 2023
Role: Co-Investigator
Description: This is a double-blind, placebo-controlled trial to assess the effect of marked LDL lowering using PCSK9 inhibition on atherosclerosis in HIV. This project evaluates the impact of PCSK9 antagonism on 3 imaging indices that are known to be abnormal in HIV: 1) arterial inflammation using FDG-PET/CT, 2) endothelial function, and 3) non-calcified plaque by CT angiography. |